FDA OKs Adjuvant Pembrolizumab for NSCLC

(MedPage Today) -- The FDA has approved pembrolizumab (Keytruda) as an adjuvant therapy following surgical resection and platinum-based chemotherapy for patients with stage IB, II, or IIIA non-small cell lung cancer (NSCLC), Merck announced. The...
Source: MedPage Today Public Health - Category: American Health Source Type: news